Partnering with
MOGRIFY
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, in vivo reprogramming and ex vivo cell therapy to develop treatments for indications of high unmet clinical need. We are particularly interested in speaking with those with interest in ophthalmology, immuno-oncology, as well as other areas of degenerative disease where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development and co-development partnerships, as well as the exploration and generation of novel therapeutic modalities.
Current
PARTNERS
Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.
MRC Laboratory for Molecular Biology
The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Duke-NUS Medical School
Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.
Monash University
The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.
Our
PIPELINE
| AREA | Sample Acquisition | Bioinformatics | In vitro PoC | In vivo PoC | IND | Clinical | Marketing |
|---|---|---|---|---|---|---|---|
| Ophthalmology (Retinal) | mogrify | mogrify | mogrify | mogrify | partner | partner | |
| Immunotherapy (Oncology) | mogrify | mogrify | mogrify | partner | partner | ||
| Collaborations (Pulmonary, Metabolic & Others) | mogrify | mogrify | mogrify | partner | partner | partner | partner |
| mogrify | Mogrify Progress | partner | Expect to Partner |
